Literature DB >> 15081522

Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling?

Caroline A Jefferies1, Luke A J O'Neill.   

Abstract

The discovery of the Toll-like receptors (TLRs) has revolutionised the field of innate immunity. One unresolved question regarding LPS signalling is whether there is a role for tyrosine kinases downstream of the LPS receptor. Studies in mice deficient in Bruton's tyrosine kinase have previously shown that they are defective in their responses to LPS. Further investigation into the role of Btk in LPS signalling has directly implicated Btk downstream of TLR4, both with respect to p38 MAPK activation and activation of the transcription factor NFkappaB. In fact Btk is activated by LPS and has been shown to directly bind TLR4 and the key proximal signalling proteins involved in LPS-induced NFkappaB activation, MyD88, Mal and IRAK-1. These recent findings point to a direct role for Btk in LPS signal transduction and raise interesting questions regarding the mode of activation of Btk following LPS stimulation and the precise nature of the pathways activated downstream of Btk. A better understanding of how Btk functions in LPS signalling will have important implications for inflammatory and autoimmune disorders and therapies thereof.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081522     DOI: 10.1016/j.imlet.2003.11.017

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  26 in total

1.  Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.

Authors:  Iván Fernández-Vega; Luis M Quirós; Jorge Santos-Juanes; María Pane-Foix; Teresa Marafioti
Journal:  Virchows Arch       Date:  2014-11-30       Impact factor: 4.064

Review 2.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

3.  Bruton Tyrosine Kinase Inhibition Attenuates Liver Damage in a Mouse Warm Ischemia and Reperfusion Model.

Authors:  Tiziana Palumbo; Kojiro Nakamura; Charles Lassman; Yoko Kidani; Steven J Bensinger; Ronald Busuttil; Jerzy Kupiec-Weglinski; Ali Zarrinpar
Journal:  Transplantation       Date:  2017-02       Impact factor: 4.939

4.  Mediators of Tyrosine Phosphorylation in Innate Immunity: From Host Defense to Inflammation onto Oncogenesis.

Authors:  Kamalika Nag; Anu Chaudhary
Journal:  Curr Signal Transduct Ther       Date:  2009-05

5.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

6.  The Tec Kinase-Regulated Phosphoproteome Reveals a Mechanism for the Regulation of Inhibitory Signals in Murine Macrophages.

Authors:  Giacomo Tampella; Hannah M Kerns; Deqiang Niu; Swati Singh; Socheath Khim; Katherine A Bosch; Meghan E Garrett; Albanus Moguche; Erica Evans; Beth Browning; Tahmina A Jahan; Mariana Nacht; Alejandro Wolf-Yadlin; Alessandro Plebani; Jessica A Hamerman; David J Rawlings; Richard G James
Journal:  J Immunol       Date:  2015-05-29       Impact factor: 5.422

7.  Role of CLIC4 in the host innate responses to bacterial lipopolysaccharide.

Authors:  Guoan He; Yao Ma; Szu-Yi Chou; Huihong Li; Chingwen Yang; Jen-Zen Chuang; Ching-Hwa Sung; Aihao Ding
Journal:  Eur J Immunol       Date:  2011-04-20       Impact factor: 5.532

8.  Transgenic mice expressing dominant-negative bright exhibit defects in B1 B cells.

Authors:  Jamee C Nixon; Scott Ferrell; Cathrine Miner; Athenia L Oldham; Ute Hochgeschwender; Carol F Webb
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

Review 9.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.

Authors:  Megan Y Murray; Lyubov Zaitseva; Martin J Auger; Jenny Io Craig; David J MacEwan; Stuart A Rushworth; Kristian M Bowles
Journal:  Cell Cycle       Date:  2015-01-07       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.